Compare Cytokinetics Inc (CYTK) vs iShares MSCI Indonesia ETF (EIDO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs iShares MSCI Indonesia ETF — how do they compare? Cytokinetics Inc trades at $81.96 (market cap $11.12B), while iShares MSCI Indonesia ETF trades at $12. The key difference: Cytokinetics Inc is trading nearer its 52-week high, iShares MSCI Indonesia ETF nearer its low. Which is the better fit depends on your goals.
| CYTK | EIDO | |
|---|---|---|
Market Cap | $11.12B | — |
Sector | Technology | — |
52-Week High | $87.26 | $19.22 |
52-Week Low | $33.23 | $10.80 |
Enterprise Value | $11.59B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
EIDO trades at $11.98, up 1.1% today, but technical indicators signal a bearish trend with moving averages and RSI_6 suggesting caution. The ETF's dividend was cut by 27% in 2025, reflecting underlying pressures. Recent news highlights Indonesia's economic initiatives, including AI integration in government programs, which could boost GDP but face currency volatility from Bank Indonesia's rate hikes to defend the rupiah.
Outlook remains mixed: potential growth from Indonesia's economic policies offers opportunity, but risks from currency instability and dividend reductions weigh on investor confidence. The bearish technical setup and lack of recent fundamental data necessitate careful evaluation of emerging market exposure amid global macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →
